-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2023-508874-27-00
5
2025-12-02
Heart condition
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-519590-19-00
4
2025-11-25
PD-L1 positive advanced colorectal cancer
-
2025-521920-31-00
4
2025-11-21
Graves’ Disease
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2025-521260-35-00
6
2025-11-07
acute ischemic stroke and atrial fibrillation (AF)
-
2025-521522-15-00
4
2025-11-05
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
-
2024-514113-35-01
6
2025-11-03
Persistent atrial fibrillation
-
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
-
2024-518521-14-00
6
2025-10-17
Critical condition
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2025-521838-29-00
3
2025-10-16
Sickle Cell Disease
-
2024-514376-40-00
4
2025-10-15
High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2025-520535-16-00
6
2025-10-10
End-stage renal disease
-
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
-
2024-517632-22-00
5
2025-10-06
Hidradenitis Suppurativa
-
2025-521975-30-00
4
2025-10-03
Newly Diagnosed Multiple Myeloma
-
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)